BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 33820510)

  • 1. MicroRNAs as Biomarkers in Hypertrophic Cardiomyopathy: Current State of the Art.
    Angelopoulos A; Oikonomou E; Vogiatzi G; Antonopoulos A; Tsalamandris S; Georgakopoulos C; Papanikolaou P; Lazaros G; Charalambous G; Siasos G; Vlachopoulos C; Tousoulis D
    Curr Med Chem; 2021; 28(36):7400-7412. PubMed ID: 33820510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy.
    Roncarati R; Viviani Anselmi C; Losi MA; Papa L; Cavarretta E; Da Costa Martins P; Contaldi C; Saccani Jotti G; Franzone A; Galastri L; Latronico MV; Imbriaco M; Esposito G; De Windt L; Betocchi S; Condorelli G
    J Am Coll Cardiol; 2014 Mar; 63(9):920-7. PubMed ID: 24161319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy.
    Fang L; Ellims AH; Moore XL; White DA; Taylor AJ; Chin-Dusting J; Dart AM
    J Transl Med; 2015 Sep; 13():314. PubMed ID: 26404540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of microRNAs in patients with hypertrophic cardiomyopathy.
    Scolari FL; Faganello LS; Garbin HI; Piva E Mattos B; Biolo A
    Int J Cardiol; 2021 Mar; 327():146-154. PubMed ID: 33212095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel miRNA Screen Identifies miRNA-4454 as a Candidate Biomarker for Ventricular Fibrosis in Patients with Hypertrophic Cardiomyopathy.
    Thottakara T; Lund N; Krämer E; Kirchhof P; Carrier L; Patten M
    Biomolecules; 2021 Nov; 11(11):. PubMed ID: 34827715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating Levels of MicroRNAs in Hypertrophic Cardiomyopathy: The Relationship With Left Ventricular Hypertrophy, Left Atrial Dilatation and Ventricular Depolarisation-Repolarisation Parameters.
    Sonsöz MR; Yilmaz M; Cevik E; Orta H; Bilge AK; Elitok A; Onur I; Komurcu-Bayrak E
    Heart Lung Circ; 2022 Feb; 31(2):199-206. PubMed ID: 34088630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-1-3p that correlates with left ventricular function of HCM can serve as a potential target and differentiate HCM from DCM.
    Li M; Chen X; Chen L; Chen K; Zhou J; Song J
    J Transl Med; 2018 Jun; 16(1):161. PubMed ID: 29885652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy.
    Ho CY; Abbasi SA; Neilan TG; Shah RV; Chen Y; Heydari B; Cirino AL; Lakdawala NK; Orav EJ; González A; López B; Díez J; Jerosch-Herold M; Kwong RY
    Circ Cardiovasc Imaging; 2013 May; 6(3):415-22. PubMed ID: 23549607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Expression of microRNAs in Hypertrophied Myocardium and Their Relationship to Late Gadolinium Enhancement, Left Ventricular Hypertrophy and Remodeling in Hypertrophic Cardiomyopathy.
    Zhang C; Zhang H; Zhao L; Wei Z; Lai Y; Ma X
    Diagnostics (Basel); 2022 Aug; 12(8):. PubMed ID: 36010328
    [No Abstract]   [Full Text] [Related]  

  • 10. Characterization of the circulating transcriptome expression profile and identification of novel miRNA biomarkers in hypertrophic cardiomyopathy.
    Guo L; Cai Y; Wang B; Zhang F; Zhao H; Liu L; Tao L
    Eur J Med Res; 2023 Jun; 28(1):205. PubMed ID: 37391825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy: Current state of the art.
    Kamal MU; Riaz IB; Janardhanan R
    Cardiol J; 2016; 23(3):250-63. PubMed ID: 27064795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The current and emerging role of cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy.
    Maron MS
    J Cardiovasc Transl Res; 2009 Dec; 2(4):415-25. PubMed ID: 20560000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood-based microRNA signatures differentiate various forms of cardiac hypertrophy.
    Derda AA; Thum S; Lorenzen JM; Bavendiek U; Heineke J; Keyser B; Stuhrmann M; Givens RC; Kennel PJ; Schulze PC; Widder JD; Bauersachs J; Thum T
    Int J Cardiol; 2015 Oct; 196():115-22. PubMed ID: 26086795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T1 Mapping in Discrimination of Hypertrophic Phenotypes: Hypertensive Heart Disease and Hypertrophic Cardiomyopathy: Findings From the International T1 Multicenter Cardiovascular Magnetic Resonance Study.
    Hinojar R; Varma N; Child N; Goodman B; Jabbour A; Yu CY; Gebker R; Doltra A; Kelle S; Khan S; Rogers T; Arroyo Ucar E; Cummins C; Carr-White G; Nagel E; Puntmann VO
    Circ Cardiovasc Imaging; 2015 Dec; 8(12):. PubMed ID: 26659373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A critical approach for successful use of circulating microRNAs as biomarkers in cardiovascular diseases: the case of hypertrophic cardiomyopathy.
    Ntelios D; Georgiou E; Alexouda S; Malousi A; Efthimiadis G; Tzimagiorgis G
    Heart Fail Rev; 2022 Jan; 27(1):281-294. PubMed ID: 33656618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular magnetic resonance T2* mapping for the assessment of cardiovascular events in hypertrophic cardiomyopathy.
    Gastl M; Gruner C; Labucay K; Gotschy A; Von Spiczak J; Polacin M; Boenner F; Kelm M; Ruschitzka F; Alkadhi H; Kozerke S; Manka R
    Open Heart; 2020; 7(1):e001152. PubMed ID: 32201584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum microRNA profiles in cats with hypertrophic cardiomyopathy.
    Weber K; Rostert N; Bauersachs S; Wess G
    Mol Cell Biochem; 2015 Apr; 402(1-2):171-80. PubMed ID: 25573325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating MicroRNAs Identify Early Phenotypic Changes in Sarcomeric Hypertrophic Cardiomyopathy.
    Sucharov CC; Neltner B; Pietra AE; Karimpour-Fard A; Patel J; Ho CY; Miyamoto SD
    Circ Heart Fail; 2023 Jun; 16(6):e010291. PubMed ID: 36880380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Cardiac Magnetic Resonance Feature Tracking (CMR-FT) Analysis for Detection of Myocardial Fibrosis in Pediatric Hypertrophic Cardiomyopathy.
    Bogarapu S; Puchalski MD; Everitt MD; Williams RV; Weng HY; Menon SC
    Pediatr Cardiol; 2016 Apr; 37(4):663-73. PubMed ID: 26833321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNAs in hypertrophic cardiomyopathy: pathogenesis, diagnosis, treatment potential and roles as clinical biomarkers.
    Luo F; Liu W; Bu H
    Heart Fail Rev; 2022 Nov; 27(6):2211-2221. PubMed ID: 35332416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.